G
GLP1 Lawsuit
Mass Tort Case Review
Call
GLP-1 Drug Injury

Ozempic & Suicidal Ideation Lawsuit

European Medicines Agency review and FDA post-marketing reports have raised concerns about new or worsening suicidal ideation in some GLP-1 users. If you experienced this and were hospitalized or required psychiatric care, you may qualify for review.

Call (717) 724-7503

Free Confidential Case Review

No fee unless you win. Takes under 60 seconds.

What regulators are investigating

The EMA opened a formal review in 2023 after multiple reports of suicidal thoughts and self-injury in patients taking semaglutide and liraglutide. The FDA also added new language to GLP-1 labels and continues to monitor the signal.

When mental-health claims may qualify

Documented new-onset suicidal ideation, suicide attempt, or psychiatric hospitalization with no prior history, beginning during or shortly after GLP-1 therapy, are the strongest factual patterns. A licensed attorney will assess your specific case.

Frequently Asked Questions

Get your free, confidential case review

Takes under 60 seconds. No fee unless you win.

Free Confidential Case Review

No fee unless you win. Takes under 60 seconds.